<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475306</url>
  </required_header>
  <id_info>
    <org_study_id>07-01-005</org_study_id>
    <nct_id>NCT00475306</nct_id>
  </id_info>
  <brief_title>The Montefiore Metoclopramide Study</brief_title>
  <official_title>A Randomized, Facorial Design Study to Optimize the Dose of Parenteral Metoclopramide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metoclopramide is a dopamine antagonist frequently used for the treatment of nausea,
      vomiting, and migraine headaches in Emergency Departments. However, little research has
      focused on the optimal dose of metoclopramide for treatment of nausea in the emergency
      department. We propose a randomized, double-blind, placebo controlled trial to investigate
      the optimal dose of metoclopramide for treatment of nausea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most effective dose of metoclopramide for treatment of nausea in the emergency department
      setting has not been thoroughly investigated. One pilot study among emergency department
      patients in Australia found no statistical difference between 10 mg and 0.4
      milligrams/kilogram; another investigation suggests that the anti-emetic effect of 10
      milligrams of metoclopramide is no more effective than placebo. In contrast, investigations
      focusing on chemotherapy patients and post-operative patients suggest that higher dosage
      metoclopramide is more effective in treating nausea and vomiting. This emergency department
      study will compare the anti-emetic efficacy of 10 milligrams and 20 milligrams of
      metoclopramide by using the visual analog scale.

      In addition to evaluation of dose, we will evaluate one of the most common side affects of
      metoclopramide, akathisia. Akathisia is characterized by a subjective component of
      restlessness and an objective component in the form of the inability to remain motionless.
      Anti-cholinergic medications are known to reduce extrapyramidal symptoms such as akathisia
      when dopamine function is impaired in the basal ganglia. In fact, the use of diphenhydramine
      has been shown to reduce the incidence of akathisia in patients receiving a different
      anti-emetic, prochlorperazine. However, no research has focused on the use of
      anti-cholinergic medications to reduce metoclopramide induced akathisia. This investigation
      will assess the use of 25 mg of diphenhydramine in preventing metoclopramide induced
      akathisia in ED patients being treated for nausea/vomiting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nausea Scale</measure>
    <time_frame>60 minutes</time_frame>
    <description>Patients were asked to report their level of nausea on a scale for 0 to 10, with 0 representing no nausea and 10 the worst nausea imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Akathisia</measure>
    <time_frame>60 minutes</time_frame>
    <description>The akathisia outcome was reported as follows: Either development of akathisia as measured using the Short Akathisia Instrument (Vinson DR. Journal of Emergency Medicine. 2006; 31:139-145)or use of rescue medication for treatment of akathisia.The short akathisia instrument briefly measures subjective and objective restlessness.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Nausea</condition>
  <condition>Extrapyramidal Symptoms</condition>
  <arm_group>
    <arm_group_label>Metoclopramide 20+diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide 20+placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide 10 + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide 10+diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide 10 mg</intervention_name>
    <description>an anti-emetic medication</description>
    <arm_group_label>Metoclopramide 10 + placebo</arm_group_label>
    <arm_group_label>Metoclopramide 10+diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine 25 mg</intervention_name>
    <description>used for prophylaxis against akathisia</description>
    <arm_group_label>Metoclopramide 20+diphenhydramine</arm_group_label>
    <arm_group_label>Metoclopramide 10+diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Metoclopramide 20+placebo</arm_group_label>
    <arm_group_label>Metoclopramide 10 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide 20 mg</intervention_name>
    <description>Metoclopramide 20 mg</description>
    <arm_group_label>Metoclopramide 20+diphenhydramine</arm_group_label>
    <arm_group_label>Metoclopramide 20+placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary or secondary complaints of nausea/vomiting

          -  age 21-65

        Exclusion Criteria:

          -  pregnancy

          -  use of anti-histamine or dopamine antagonist as outpatient and/or within last 24 hours
             of presentation

          -  previous adverse reaction to study medications

          -  use of opioid medications prior to study start time within that ED visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brooke Bender, MD</last_name>
    <role>Study Director</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>July 11, 2011</results_first_submitted>
  <results_first_submitted_qc>November 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2012</results_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Friedman</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Metoclopramide</keyword>
  <keyword>Nausea</keyword>
  <keyword>Akathisia</keyword>
  <keyword>Emergency department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who presented to one ED with nausea were eligible for participation</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metoclopramide 20 mg+Diphenhydramine</title>
          <description>Metoclopramide 20mg co-administered with diphenhydramine 25 mg, intravenously</description>
        </group>
        <group group_id="P2">
          <title>Metoclopramide 20+Placebo</title>
          <description>Metoclopramide 20 mg co-administered with placebo, intravenously</description>
        </group>
        <group group_id="P3">
          <title>Metoclopramide 10 + Placebo</title>
          <description>Metoclopramide 10 mg co-administered with placebo, intravenously</description>
        </group>
        <group group_id="P4">
          <title>Metoclopramide 10+Diphenhydramine</title>
          <description>Metoclopramide 10 mg co-administered with diphenhydramine 25 mg, intravenously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72">1 patient had resolution of nausea prior and did not receive the investigational medication</participants>
                <participants group_id="P2" count="71">For 1 patient, data collection was incomplete and results could not be analyzed</participants>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="71">1 patient's intravenous line infiltrated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoclopramide 20mg+Diphenhydramine</title>
          <description>Metoclopramide 20 mg co-administered with diphenhydramine 25mg, intravenously</description>
        </group>
        <group group_id="B2">
          <title>Metoclopramide 20+Placebo</title>
          <description>Metoclopramide 20 mg co-administered with placebo, intravenously</description>
        </group>
        <group group_id="B3">
          <title>Metoclopramide 10 + Placebo</title>
          <description>Metoclopramide 10 mg co-administered with placebo, intravenously</description>
        </group>
        <group group_id="B4">
          <title>Metoclopramide 10+Diphenhydramine</title>
          <description>Metoclopramide 10mg co-administered with diphenhydramine 25mg, intravenously</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="286"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="12"/>
                    <measurement group_id="B2" value="42" spread="14"/>
                    <measurement group_id="B3" value="40" spread="13"/>
                    <measurement group_id="B4" value="39" spread="13"/>
                    <measurement group_id="B5" value="40" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Please note: Only patients who completed the study are reported here</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nausea Scale</title>
        <description>Patients were asked to report their level of nausea on a scale for 0 to 10, with 0 representing no nausea and 10 the worst nausea imaginable</description>
        <time_frame>60 minutes</time_frame>
        <population>Only patients who received the investigational medication are included in this analysis. Please see the participant flow section for more details.</population>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide 20mg+Diphenhydramine</title>
            <description>Metoclopramide 20 mg co-administered with diphenhydramine 25mg, intravenously</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide 20+Placebo</title>
            <description>Metoclopramide 20 mg co-administered with placebo, intravenously</description>
          </group>
          <group group_id="O3">
            <title>Metoclopramide 10 + Placebo</title>
            <description>Metoclopramide 10 mg co-administered with placebo, intravenously</description>
          </group>
          <group group_id="O4">
            <title>Metoclopramide 10+Diphenhydramine</title>
            <description>Metoclopramide 10mg co-administered with diphenhydramine 25mg, intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea Scale</title>
          <description>Patients were asked to report their level of nausea on a scale for 0 to 10, with 0 representing no nausea and 10 the worst nausea imaginable</description>
          <population>Only patients who received the investigational medication are included in this analysis. Please see the participant flow section for more details.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Akathisia</title>
        <description>The akathisia outcome was reported as follows: Either development of akathisia as measured using the Short Akathisia Instrument (Vinson DR. Journal of Emergency Medicine. 2006; 31:139-145)or use of rescue medication for treatment of akathisia.The short akathisia instrument briefly measures subjective and objective restlessness.</description>
        <time_frame>60 minutes</time_frame>
        <population>Only patients who received the investigational medication are included in this analysis. Please see participant flow for details</population>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide 20mg+Diphenhydramine</title>
            <description>Metoclopramide 20 mg co-administered with diphenhydramine 25mg, intravenously</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide 20+Placebo</title>
            <description>Metoclopramide 20 mg co-administered with placebo, intravenously</description>
          </group>
          <group group_id="O3">
            <title>Metoclopramide 10 + Placebo</title>
            <description>Metoclopramide 10 mg co-administered with placebo, intravenously</description>
          </group>
          <group group_id="O4">
            <title>Metoclopramide 10+Diphenhydramine</title>
            <description>Metoclopramide 10mg co-administered with diphenhydramine 25mg, intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Akathisia</title>
          <description>The akathisia outcome was reported as follows: Either development of akathisia as measured using the Short Akathisia Instrument (Vinson DR. Journal of Emergency Medicine. 2006; 31:139-145)or use of rescue medication for treatment of akathisia.The short akathisia instrument briefly measures subjective and objective restlessness.</description>
          <population>Only patients who received the investigational medication are included in this analysis. Please see participant flow for details</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metoclopramide 20mg+Diphenhydramine</title>
          <description>Metoclopramide 20 mg co-administered with diphenhydramine 25mg, intravenously</description>
        </group>
        <group group_id="E2">
          <title>Metoclopramide 20+Placebo</title>
          <description>Metoclopramide 20 mg co-administered with placebo, intravenously</description>
        </group>
        <group group_id="E3">
          <title>Metoclopramide 10 + Placebo</title>
          <description>Metoclopramide 10 mg co-administered with placebo, intravenously</description>
        </group>
        <group group_id="E4">
          <title>Metoclopramide 10+Diphenhydramine</title>
          <description>Metoclopramide 10mg co-administered with diphenhydramine 25mg, intravenously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. BW Friedman</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

